CLVLF News Alert Clinuvel Pharm Ords (CLVLF) 3.5000 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Clinuvel Pharm Ords (CLVLF) 3.5000 $CLVLF

Vitiligo - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/sp334p/vitiligo) has announced the addition of the "Vitiligo - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Vitiligo, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vitiligo and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Vitiligo - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Vitiligo pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Reliance Life Sciences - Biocon Limited - Galderma - Sun Pharmaceutical Industries - Clinuvel Pharmaceuticals - Ache Laboratorios Farmaceuticos - SWITCH Biotech For more information visit http://www.researchandmarkets.com/research/sp334p/vitiligo

Market Maker Surveillance Report. RITT, GNI, GTI, GLYC, CLVLY, PULS, Losing Stocks With Lowest Price Friction For Friday, September 26th 2014
M2 - Mon Sep 29, 2:48AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4860 companies with "abnormal" market making, 3007 companies with positive Friction Factors and 1840 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Friday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Rit Technologies Ltd (NASDAQ:RITT), Great Northern Iron Ore Properties (NYSE:GNI), Graftech International Ltd (NYSE:GTI), GLYCOMED INC (NASDAQ:GLYC), Clinuvel Pharmaceuticals Ltd (OTC:CLVLY), Pulse Electronics Corp (NYSE ULS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
GLYC: 7.81 (-0.42), GTI: 4.84 (-0.04), RITT: 0.94 (-0.02), GNI: 18.28 (+0.18)

Retrophin plans to buy remaining shares in Clinuvel Pharmaceuticals in all cash offer
M2 - Mon Jul 28, 6:13AM CDT
Pharmaceutical company Retrophin (NasdaqGM:RTRX) on Sunday announced its proposal to acquire all of the remaining shares of Clinuvel Pharmaceuticals (ASX:CUV.AX).
RTRX: 12.92 (+0.19)

Retrophin Proposes Acquisition of Clinuvel Pharmaceuticals
Business Wire - Sun Jul 27, 10:47PM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced that on July 17, 2014 it submitted a proposal to the Board of Directors of Clinuvel Pharmaceuticals Ltd (ASX:CUV) to acquire by scheme of arrangement all of the shares of Clinuvel stock that Retrophin does not own for (1) 0.175 Retrophin shares per Clinuvel share, or (2) A$2.17 per share in cash. Retrophin currently owns approximately 4.88% of Clinuvel shares.
RTRX: 12.92 (+0.19)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 22

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
YYForce Security Win Adds Recurring Singapore Revenue Base

Updated Category News Views 160

A retail-property security mandate rarely makes anyone pound the table, and frankly it should not. Still, YYForce has landed a tangible two-year contract in Singapore worth roughly S$831,120, with subsidiary Uniforce Security Services set to begin work on December 1, 2026. For NASDAQ:YFOR investors, this is the kind of small, operationally real win that deserves a sober...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 58

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Niron's $1.8B Alabama Bet Carries Big Magnet Stakes

Updated Category News Views 54

A Huge Factory Claim Needs More Than Applause A magnet company just tossed a very large number onto Alabama's economic-development table. Niron Magnetics says it plans a $1.8 billion investment in the state that would create 700 jobs. That is not pocket change, not a ribbon-cutting trinket, and not the sort of announcement investors should breeze past between earnings...

Continue Reading
Appian Survey Flags AI Aloneware Maintenance Drag Risk

Updated Category News Views 58

A bot can spit out a feature before lunch, then leave a repair bill nobody budgeted for. That is the uncomfortable issue behind Appian's new research on AI-assisted software development: speed is easy to celebrate, while ownership gets shoved into a dark corner until something breaks. Appian said on November 20, 2026, that two-thirds of surveyed AI decision-makers and IT...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 75

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 82

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 67

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 76

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading

Top 5 Most Recently Viewed Articles

Organon & Co. Class Action Lawsuit: Key Details You Should Know

Updated Category News Views 221

Overview of the Class Action Lawsuit Against Organon & Co. The latest developments in the class action lawsuit regarding Organon & Co. (NYSE: OGN) have attracted attention from investors. The lawsuit is aimed at representing purchasers of Organon's publicly traded securities during a specific time frame. Robbins Geller Rudman & Dowd LLP has taken the lead in filing this...

Continue Reading
JINRO Partners with BTS's V: A Strategic Move

Updated Category News Views 25

What's Brewing Between JINRO and BTS's V? Picture this: you're wandering the aisles of an international market, see a splashy new bottle of soju, and notice V from BTS smiling from the label. That's right, folks, JINRO, the world's reigning soju brand, has just snagged a partnership with BTS's V to serve up a global brand punch. This move isn't just a pretty face on a...

Continue Reading
Latin Metals Unveils Exciting Spin-Out Plan for Copper Assets

Updated Category News Views 172

Latin Metals Moves Forward with Spin-Out of Peruvian Assets Latin Metals Inc. (TSXV: LMS, OTCQB: LMSQF) is charting a new course by announcing its decision to spin-out certain Peruvian exploration projects into a newly founded subsidiary named Latin Explore. This strategic move aims to unlock value for shareholders while maintaining a robust exploration agenda. Overview...

Continue Reading
McCormick's Resilience Shines Amidst Economic Challenges

Updated Category News Views 66

McCormick Challenges and Growth Strategy McCormick & Company, Inc. (NASDAQ: MKC) recently announced its third-quarter earnings, revealing a solid financial performance, even in a tough consumer environment. The company achieved a 1% volume growth in its Consumer segment and steady sales in its Flavor Solutions segment, showcasing a strong market presence despite...

Continue Reading
Goodyear's Financial Performance Amidst Industry Challenges

Updated Category News Views 248

Understanding Goodyear's Recent Earnings Report Goodyear Tire & Rubber Co (NASDAQ: GT) has reported its recent financial results, particularly highlighting the challenges faced during the second quarter of their fiscal year 2025. This period proved to be quite turbulent after the closing bell, reflecting considerable disruptions in their operating environment that...

Continue Reading